Kimura Hideki, Yasufuku Kazuhiro, Ando Soichiro, Yoshida Shigetosi, Ishikawa Aki, Wada Yoshinobu, Fujisawa Takehiko
Division of Thoracic Diseases, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan.
Lung Cancer. 2007 Jun;56(3):349-55. doi: 10.1016/j.lungcan.2007.01.018. Epub 2007 Apr 27.
A prospective phase II study of indications for surgery, using video-assisted mediastinoscopy (VAM) to detect mediastinal lymph node metastasis was conducted in patients with resectable primary lung cancer of clinical stages I-IIIA. According to the indication criteria for VAM, Group A patients had primary tumor resection and lymph node sampling without VAM. Patients without detected metastasis by VAM underwent thoracotomy and systematic lymph node dissection (Group B). Cases with mediastinal lymph node involvement confirmed by VAM were treated with chemotherapy followed by radiotherapy (Group D) or by thoracotomy (Group C) with extended dissection of mediastinal lymph nodes via median sternotomy. Of the 359 eligible patients, 209 underwent VAM (Group V) and 150 had thoracotomy without VAM (Group A). Of the VAM patients, 158 were negative for mediastinal involvement and underwent thoracotomy (Group B). Fifty-one patients had metastases and were given chemotherapy or chemo-radiotherapy. After two courses of chemotherapy, 22 patients with partial response (PR) or stable disease (SD) but reduced tumor markers received surgery with mediastinal lymph node dissection (Group C). The 2- and 5-year survival rates were 93.0 and 88.5% for Group A, and 89.5 and 61.5% for Group B, while the 2-year rate in Group C was 60.3%. In stage IA patients, Group A 2- and 5-year survival rates were 98.6 and 95.1%, the respective Group B rates being 96.3 and 89.9%. The more favorable Group A outcomes indicated both successful selection by these criteria of patients not requiring mediastinal examination, and the superfluity of complete lymph node dissection in early stage cancer.
对临床分期为I-IIIA期的可切除原发性肺癌患者进行了一项前瞻性II期研究,采用电视辅助纵隔镜检查(VAM)来检测纵隔淋巴结转移情况。根据VAM的适应证标准,A组患者在未进行VAM的情况下进行了原发性肿瘤切除和淋巴结采样。VAM未检测到转移的患者接受了开胸手术和系统性淋巴结清扫(B组)。经VAM确诊纵隔淋巴结受累的病例接受化疗后放疗(D组)或通过正中胸骨切开术进行开胸手术(C组),并扩大纵隔淋巴结清扫范围。在359例符合条件的患者中,209例接受了VAM(V组),150例未进行VAM直接接受了开胸手术(A组)。在接受VAM的患者中,158例纵隔无受累,接受了开胸手术(B组)。51例患者有转移,接受了化疗或放化疗。经过两个疗程的化疗后,22例部分缓解(PR)或病情稳定(SD)但肿瘤标志物降低患者接受了纵隔淋巴结清扫手术(C组)。A组的2年和5年生存率分别为93.0%和88.5%,B组分别为89.5%和61.5%,而C组的2年生存率为60.3%。在IA期患者中,A组的2年和5年生存率分别为98.6%和95.1%,B组分别为96.3%和89.9%。A组更优的结果表明,通过这些标准成功筛选出了不需要进行纵隔检查的患者,并且早期癌症进行完全淋巴结清扫是多余的。